therapy and the metabolic flare phenomenon will not be present. In normal bones, ¹⁸F-fluoride has a diffuse and uniform uptake, and we believe that this will not mask the focal and intense ¹⁸F-FDG uptake in bone marrow metastases. Of course, these hypotheses remain to be demonstrated in studies with larger cohorts.

REFERENCES

- Iagaru A, Mittra E, Yaghoubi SS, et al. Novel strategy for a cocktail ¹⁸F-fluoride and ¹⁸F-FDG PET/CT scan for evaluation of malignancy: results of the pilotphase study. *J Nucl Med.* 2009;50:501–505.
- Hoegerle S, Juengling F, Otte A, Altehoefer C, Moser EA, Nitzsche EU. Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? *Radiology*. 1998;209:253–258.
- Cook GJ, Fogelman I. Detection of bone metastases in cancer patients by ¹⁸Ffluoride and ¹⁸F-fluorodeoxyglucose positron emission tomography. Q J Nucl Med. 2001;45:47–52.

 Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by ¹⁸FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. *J Clin Oncol.* 1998;16:3375–3379.

Andrei Iagaru Erik Mittra Michael L. Goris Sanjiv S. Gambhir

*Stanford University 318 Campus Dr. East Wing, First Floor, Room E150A Stanford, CA 94305 E-mail: sgambhir@stanford.edu

DOI: 10.2967/jnumed.109.067082

Erratum

In the article "Using Dual-Tracer PET to Predict the Biologic Behavior of Human Colorectal Cancer," by Hui et al. (*J Nucl Med.* 2009;50:1857–1864), the byline mistakenly indicated that 3 of the authors contributed equally. However, only Wang Hui and Zhang Jinming contributed equally to the work. We regret the error.